Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.59
    -0.01 (-0.08%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Pharming Group NV (PHAR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Pharming Group NV (PHAR) to earn $0.26 per share in the fiscal year ending Dec 31, 2026, on revenue of $387.34M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 30.8% and revenue estimates rise 9.0%.

    Fiscal year ending Dec 31, 2026
    $0.26
    EPS consensus, revenue $387.34M
    Fiscal year ending Dec 31, 2027
    $0.18
    EPS consensus, revenue $422.02M
    Fiscal year ending Dec 31, 2028
    $0.36
    EPS consensus, revenue $428.40M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.26$0.04 to $0.482$387.34M$381.40M to $394.90M5
    Dec 31, 2027$0.18$0.04 to $0.322$422.02M$407.80M to $451.99M5
    Dec 31, 2028$0.36$0.34 to $0.391$428.40M$409.31M to $459.47M1

    Quarterly Estimates

    The EPS consensus falls from $0.02 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.02$0.02 to $0.035$116.62M$110.96M to $118.88M5
    Mar 31, 2027-$0.01-$0.01 to -$0.011$77.00M$77.00M to $77.00M1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202702
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 13.0% from $0.23.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.26$0.61$0.46$0.46$0.23+12.9%
    Fiscal year ending Dec 31, 2027$0.18$0.07$0.31$0.31$0.07+174.8%

    Frequently Asked Questions About PHAR

    What is the PHAR stock forecast?

    Consensus analyst estimates put Pharming Group NV's EPS at $0.26 for the fiscal year ending Dec 31, 2026, on revenue of $387.34M. The consensus rating from 4 analysts is Buy.

    How do analysts rate PHAR stock?

    Of 4 analysts covering Pharming Group NV, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PHAR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.26, with estimates from $0.04 to $0.48 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.18, with estimates from $0.04 to $0.32 from 2 analysts.

    What revenue do analysts expect from Pharming Group NV next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $387.34M, with estimates from $381.40M to $394.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $422.02M, with estimates from $407.80M to $451.99M.

    How many analysts cover PHAR?

    4 analysts rate Pharming Group NV stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.